1 / 3

Application of Lipid Nanoparticles in COVID-19 mRNA Vaccines Huateng

Currently, the approved mRNA COVID-19 vaccines (Table 1) are utilizing LNP technology. This illustrates the successes achieved with this type of nanoparticle to stabilize mRNA and successfully deliver it into cells. To be specific, LNPs have two advantages as an mRNA vaccine vector. On the one hand, LNPs defend mRNA from degradation by enzymes from the endosome. The characteristic guarantees high encapsulation efficiency. On the other hand, LNPs have good biocompatibility through a series of biological processes to deliver mRNAs for expression.

sunnyfang1419
Download Presentation

Application of Lipid Nanoparticles in COVID-19 mRNA Vaccines Huateng

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Huateng Pharma https://en.huatengsci.com Application of Lipid Nanoparticles in COVID-19 mRNA Vaccines Of the 14 approved COVID-19 vaccines in the market, the vaccines developed by BioNTech/Pfizer and Moderna has received widespread attention from all over the world, which represent a new class of vaccine products: they are composed of messenger ribonucleic acid (mRNA) strands encapsulated in lipid nanoparticles (LNPs). mRNA vaccines are new types of vaccines that have aroused great interest. The main challenge for their applications is how to ensure their effective delivery. This is because the physicochemical properties of mRNA (such as negative charge and hydrophilicity) hinder the passive diffusion of mRNA vaccines through the plasma membrane. Moreover, mRNA vaccines are also susceptible to nuclease degradation. For example, free mRNA will quickly decompose in the body, greatly reducing its effectiveness. It is necessary to use advanced technology to avoid this situation, thereby improving the stability of the vaccine, and this is where the lipid nanoparticles(LNPs) come into play. Currently, the approved mRNA COVID-19 vaccines (Table 1) are utilizing LNP technology. This illustrates the successes achieved with this type of nanoparticle to stabilize mRNA and successfully deliver it into cells. To be specific, LNPs have two advantages as an mRNA vaccine vector. On the one hand, LNPs defend mRNA from degradation by enzymes from the endosome. The characteristic guarantees high encapsulation efficiency. On the other hand, LNPs have good biocompatibility through a series of biological processes to deliver mRNAs for expression. Category Product Name mRNA dose Route of administration Pfizer-BioNTech mRNA vaccine BNT162b2/Tozinameran/Comirnaty 30 µg Moderna mRNA vaccine mRNA-1273 100 µg intramuscular intramuscular

  2. Huateng Pharma ALC-0315 = (4-hydroxybutyl) azanediyl)bis (hexane-6,1-diyl)bis(2-hexyldecanoate) ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N ditetradecylacetamide 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) Cholesterol Potassium dihydrogen phosphate Disodium hydrogen phosphate dihydrate Potassium chloride Sodium chloride Sucrose Water for injection https://en.huatengsci.com SM-102=(heptadecan-9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate} PEG2000-DMG = 1-monomethoxypolyethyleneglycol-2,3-dimyristylglycerol with polyethylene glycol (2000) 1,2-Distearoyl-sn-glycero-3 phosphocholine (DSPC) Cholesterol Lipid nanoparticle components Buffer Tris (tromethamine) Sodium acetate Sucrose Water for injection Other excipients Table 1:Approved mRNA COVID-19 vaccines The LNPs in mRNA COVID-19 vaccines consist of four main components: a neutral phospholipid, cholesterol, a polyethylene-glycol (PEG)-lipid, and an ionizable cationic lipid, among them, PEG can enhance the stability and lifespan of LNPs. According to public information, PEG has never appeared in any other vaccines in the world. This will be another new application of PEG in the field of medicine. The structure of lipid nanoparticle vaccine carrier: mRNA organized in reverse lipid micelles in the nanoparticles (A); mRNA embedded between lipid bilayers (B) Huateng Pharma is a dynamic science company dedicated to PEG derivatives and intermediates. We are capable of supplying small to large quantities of a

  3. Huateng Pharma rich selection of PEG derivatives with unique molecular designs (chemical structure, molecular weights (MW)) to serve bio-technology and pharmaceutical companies and research organizations worldwide. We can supply the following PEG products used in COVID-19 vaccines. https://en.huatengsci.com 1. ALC-0159, mPEG-N,N-Ditetradecylacetamide, CAS No. 1849616-42-7 2. mPEG-DMG, CAS NO. 160743-62-4 3. mPEG-CH2CH2CH2-NH2 4. mPEG-CM ​ 5. mPEG-OH, CAS NO. 9004-74-4

More Related